Literature DB >> 24339538

Hemoglobin E disorder: Newborn screening program.

Viroj Wiwanitkit1.   

Abstract

Hemoglobin E (Hb E) disorder is an important kind of hemoglobinopathy. It can be seen around the world with the highest prevalence in Southeast Asia. The screening for this disorder becomes the public health policies in many countries. The screening can be performed in several population groups. The newborn screening program for Hb E disorder is an important issue in pediatric genetics. In this brief review, the author discusses on important laboratory tests for screening for Hb E disorder in newborn.

Entities:  

Keywords:  Hemoglobin E; newborn; screening

Year:  2013        PMID: 24339538      PMCID: PMC3841550          DOI: 10.4103/0971-6866.120808

Source DB:  PubMed          Journal:  Indian J Hum Genet        ISSN: 1998-362X


Introduction

The congenital hemoglobin disorder is an important group of a genetic disorder.[1] This becomes an important pediatric genetic problem that can be seen around the world. The considerable high incidence of the congenital hemoglobin disorder, comparing with other genetic disorders, draws the attention of the pediatricians to focus on this disorder.[2] There are several kinds of congenital hemoglobin disorders. Hemoglobin E (Hb E) disorder is an important kind of hemoglobinopathy.[2] It can be seen around the world with the highest prevalence in Southeast Asia.[3] Although the disease form of this disease is not severe, only anemic presentation, it can be deadly if co-present with beta-thalassemia.[45] The screening for this disorder becomes the public health policies in many countries.[67] The screening can be performed in the several population groups. The newborn screening program for Hb E disorder is an important issue in pediatric genetics.[89] In this brief review, the author discusses on important laboratory tests for screening for Hb E disorder in newborn.

High Performance Liquid Chromatography Screening

In general, High Performance Liquid Chromatography (HPLC) can be used for testing for the presence of abnormal hemoglobin.[10] Several hemoglobinopathies including to Hb E can be identified by HPLC. Dried blood spot specimens can be tested by HPLC.[1112] The HPLC is presently used in some countries like USA for neonatal screening for Hb E disorder.[1112] The screening is set due to the influx of migrant from Southeast Asia to USA in the recent years.[1112] Focusing on the technique, the automated HPLC can be available.[1112] In general, the positive result usually requires further investigation by pediatric hematologist for further assessment and ruling out the possible thalassemic co-presentation.[13] For discrimination, Lorey et al. studied the “Hb F and Hb E relative percentages obtained in the newborn's HPLC result” and reported that “the percentage of Hb E was markedly lower in neonates with Hb E/beta-thalassemia versus those, which were homozygous EE.”[14]

Hemoglobin Electrophoresis Screening

Hemoglobin electrophoresis is a classical tool for determination of Hb E. This tool is still the present gold standard for screening in the several populations in the endemic areas.[151617] The cord blood can be collected for classical gel electrophoresis and used in screening.[18] However, the use of this technique in the neonatal screening for Hb E disorder is not widely used because the present policy in an endemic country shifts to the pregnancy screening.[17]

DichlorophenolIndophenol Precipitation Test Screening

DichlorophenolIndophenol Precipitation (DCIP) is the simple test that can be used for determining unstable hemoglobinopathies including to Hb E.[19] In Thailand, the endemic area of Hb E, DCIP becomes that main tool for screening for Hb E disorder. However, as noted, the screening is recommended for the pregnant.[1720]

Complete Blood Count Screening

The use of Complete Blood Count (CBC) screening for Hb E in the newborn is also mentioned. There are some reports on the use of automated CBC analyzer for assessment of red blood cell parameters and usefulness in screening Hb E disorder. For the endemic area, very good screening result is reported.[21] However, the specificity is very poor.[21] For screening, the cord blood is required and this might be inconvenient. Furthermore, the availability of the automated analyzer is the main obstacle to implement this technique widely.

Polymerase Chain Reaction Test Screening

The molecular genetics analysis the new hope for screening for congenital genetic disorder including to hemoglobinopathy.[22] For Hb E screening, it is no doubt that post-coital test provides more reliable result comparing with those previously mentioned. Direct analysis of patient deoxyribonucleic acid samples can be performed and give rapid and highly accurate result.[23] However, focusing on the cost-effectiveness, the PCR test screening is not appropriate.[17]

Other Screenings

In addition to the already mentioned methods, there are also other alternative for screening of Hb E disorders. Isoelectric focusing, an adapted electrophoresis test, is the first alternative to be mentioned.[2425] It is proved for its reliability in cord blood testing.[24] The other method is tandem mass spectrometry.[25] The reliable result can be derived.[25] However, these two techniques are limitedly used in screening for any hemoglobinopathies due to the difficulty of the technique.

Conclusion

Hb E disorder is an important hemoglobinopathy with its highest prevalence in Southeast Asia. The screening for this disorder is included in the national policies of the endemic area, but the screening is recommended for the pregnant. For the newborn group, the screening for Hb E disorder is carried out in some settings like USA focusing on the migrant.[2627] The widely used technique is HPLC.
  27 in total

1.  Hemoglobin electrophoresis in Thai non-anemic pregnant subjects, a need for additional screening for hemoglobin E.

Authors:  Nara Paritpokee; Viroj Wiwanitkit; Jamsai Suwansaksri
Journal:  Clin Chem Lab Med       Date:  2002-11       Impact factor: 3.694

2.  Cord blood screening for alpha-thalassemia and hemoglobin variants by isoelectric focusing in northern Thai neonates: correlation with genotypes and hematologic parameters.

Authors:  Pimlak Charoenkwan; Rawee Taweephol; Supatra Sirichotiyakul; Watcharee Tantiprabha; Rattika Sae-Tung; Sudjai Suanta; Pimonrat Sakdasirisathaporn; Torpong Sanguansermsri
Journal:  Blood Cells Mol Dis       Date:  2010-03-17       Impact factor: 3.039

3.  Detection of Hb E/beta-thalassemia versus homozygous EE using high-performance liquid chromatography results from newborns.

Authors:  F W Lorey; G C Cunningham; E Vichinsky; B Lubin; F Shafer; J Eastman
Journal:  Biochem Med Metab Biol       Date:  1993-02

4.  Changes in the epidemiology of thalassemia in North America: a new minority disease.

Authors:  Elliott P Vichinsky; Eric A MacKlin; John S Waye; Fred Lorey; Nancy F Olivieri
Journal:  Pediatrics       Date:  2005-11-15       Impact factor: 7.124

5.  Automated HPLC screening of newborns for sickle cell anemia and other hemoglobinopathies.

Authors:  J W Eastman; R Wong; C L Liao; D R Morales
Journal:  Clin Chem       Date:  1996-05       Impact factor: 8.327

Review 6.  Changing patterns of thalassemia worldwide.

Authors:  Elliott P Vichinsky
Journal:  Ann N Y Acad Sci       Date:  2005       Impact factor: 5.691

Review 7.  Thalassemia and abnormal hemoglobin.

Authors:  Suthat Fucharoen; Pranee Winichagoon
Journal:  Int J Hematol       Date:  2002-08       Impact factor: 2.490

8.  Asian immigration and public health in California: thalassemia in newborns in California.

Authors:  F Lorey
Journal:  J Pediatr Hematol Oncol       Date:  2000 Nov-Dec       Impact factor: 1.289

Review 9.  Haemoglobinopathies in southeast Asia.

Authors:  Suthat Fucharoen; Pranee Winichagoon
Journal:  Indian J Med Res       Date:  2011-10       Impact factor: 2.375

Review 10.  Hb E/beta-thalassaemia: a common & clinically diverse disorder.

Authors:  Nancy F Olivieri; Zahra Pakbaz; Elliott Vichinsky
Journal:  Indian J Med Res       Date:  2011-10       Impact factor: 2.375

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.